Markus GershaterChief Scientific Officer and Co-Founder
Markus co-founded Synthace after working as a Research Associate in Synthetic Biology at University College London where he developed novel biosynthesis methods using pathway engineering.
Prior to UCL, he was a Biotransformation Scientist at Novacta Biosystems working as part of the industrial biotechnology group that conducted more than 90 contract research projects for over 20 clients. Markus has a PhD in Plant Biochemistry from Durham.
COVID Vaccine Development was Astonishing, but Therapeutics Discovery and Development aren’t Solved
Our CSO and Co-Founder discusses the astounding pace of the COVID vaccine development and how we need to apply what we've learned to future R&D.
Synthace Partners with Tecan
This will transform process development cycles, reduce costs and accelerate the production of biologics and advanced therapies